Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVID-6: VGA039 prophylaxis in von Willebrand disease
2025-522056-10-01Phase 3Authorised
- Sponsor
- Vega Therapeutics
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of vga039 in von Willebrand disease (VWD), sponsored by Vega Therapeutics. Primary endpoint: Annualized bleeding rate (ABR). Planned start Mar 2026; status: authorised.
02
Drugs
vga039
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2025-522056-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522056-10-01.